PCDH15

Across TCGA pan-cancer cohorts, PCDH15 Mutation is linked to patient survival in 15 of 34 cancer types, making it a survival-associated PCDH15 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher PCDH15 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PCDH15 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

LIHC, KIRP, and DLBC are the cancer types where PCDH15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	II,III,IV	0.138	0.440	<.001	19	view →
KIRP	OS	Median	II,III,IV	0.148	0.771	<.001	18	view →
DLBC	DFS	Median	IV	0.120	0.683	.001	15	view →
ESCA	OS	Median	II,III,IV	0.103	0.868	<.001	14	view →
KIRC	OS	Median	II,III,IV	0.172	0.696	.030	12	view →
UCEC	DFS	Median	All	0.880	0.606	.012	12	view →
STAD	DFS	Median	III,IV	0.328	0.607	.005	9	view →
TGCT	DFS	Median	All	0.065	0.674	.002	6	view →
PAAD	DFS	Median	All	0.175	0.511	.016	6	view →
READ	OS	Median	IV	0.289	0.899	<.001	5	view →
ACC	DFS	Median	All	0.160	0.680	.001	5	view →
LUAD	OS	Median	All	0.153	0.406	.024	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

PCDH15–LIHC (DFS)

Open the LIHC breakdown →